Belzutifan (Welireg; Merck) demonstrated superior progression-free survival compared to everolimus in advanced renal cell carcinoma.
FDA Updates
Advertisement
The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.
Advertisement
Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
4
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
5